for more than 75 years, grifols has been improving the health and well-being of people. our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. the grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine. grifols has three business divisions: bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. research novel technologies to further improve treatment outcomes and laboratory efficiency. hospital specializes in non-biological pharmaceutical products. t
Company profile
Ticker
GRFS, GIKLY, GIFLF, GIFOF
Exchange
CEO
Raimon Grifols Roura / Victor Grifols Deu
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
GRFS stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
23 Apr 24
20-F
2023 FY
Annual report (foreign)
19 Apr 24
6-K
Current report (foreign)
18 Apr 24
6-K
Current report (foreign)
10 Apr 24
6-K
Current report (foreign)
5 Apr 24
6-K
Current report (foreign)
4 Apr 24
6-K
Current report (foreign)
2 Apr 24
6-K
Current report (foreign)
21 Mar 24
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
8 Mar 24
Latest ownership filings
SC 13G/A
BRANDES INVESTMENT PARTNERS, LP
9 Feb 24
SC 13G
BRANDES INVESTMENT PARTNERS, LP
9 Feb 24
SC 13G/A
Grifols SA
10 Jul 19
SC 13G
Grifols SA
13 Feb 19
SC 13D/A
TiGenix NV
19 Jun 18
SC 13G/A
Grifols SA
7 Feb 18
SC 13D
TiGenix NV
8 Jan 18
SC 13G
TiGenix NV
13 Jul 17
4
ARADIGM CORP
4 Apr 17
SC 13D/A
ARADIGM CORP
4 Apr 17
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
44.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 128 |
Opened positions | 15 |
Closed positions | 15 |
Increased positions | 47 |
Reduced positions | 39 |
13F shares | Current |
---|---|
Total value | 1.06 tn |
Total shares | 117.34 mm |
Total puts | 203.70 k |
Total calls | 31.20 k |
Total put/call ratio | 6.5 |
Largest owners | Shares | Value |
---|---|---|
Capital World Investors | 19.63 mm | $179.41 bn |
Millennium Management | 13.90 mm | $127.01 bn |
Brandes Investment Partners | 11.06 mm | $101.10 bn |
Black Creek Investment Management | 9.57 mm | $87.51 bn |
Flat Footed | 9.30 mm | $85.00 bn |
Pictet Asset Management Holding | 6.83 mm | $62.44 bn |
FIL | 4.54 mm | $41.51 bn |
First Trust Advisors | 4.38 mm | $40.05 bn |
Capital Research Global Investors | 4.33 mm | $39.59 bn |
Point72 Asset Management | 3.53 mm | $32.23 bn |
News
Grifols Achieves Results From Phase 4 Study Of Fanhdi In Patients With Von Willebrand Disease
22 Apr 24
CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
11 Apr 24
Grifols Achieves Milestone In Transfusion Medicine With CE Mark For Procleix ArboPlex Assay
4 Apr 24
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
22 Mar 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
22 Mar 24
Press releases
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
18 Apr 24
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
4 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
31 Mar 24
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman
29 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
27 Mar 24